Iovance Biotherapeutics, Inc. (IOVA) Stock

Iovance Biotherapeutics, Inc. (IOVA) is a Healthcare stock trading at $3.91 (as of 2026-06-18), with a market capitalization of $1.83B and a trailing P/E of -4.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company developing cancer immunotherapy products, including lifileucel and LN-145, for conditions such as metastatic melanoma, recurrent or persistent cervical cancer, and recurrent or metastatic head and neck squamous cell carcinoma. It operates multiple phase 2 studies and works through collaborations and licensing with academic medical centers and other partners.

Valuation — source: SEC EDGAR (first-party)
Price$3.91
Market Cap$1.83B
P/E Ratio-4.5
EV / EBITDA-4.6
Price / Book2.54
Price / Sales6.41
DCF Value (model)$-13.48
DCF Upside vs Price-444.8%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$263.50M
Net Margin-148.4%
Return on Equity-49.0%
Current Ratio3.60
Revenue Growth (YoY)44.8%
EPS Growth (YoY)-47.2%
FCF Growth (YoY)-28.4%
Financial Health — source: SEC EDGAR
Altman Z-Score-0.52 (distress)
Valuation vs Sector & Industry
Stock P/E-4.5
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-121.3%
vs Industry-125.8%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($109.09M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOFrederick G. Vogt
Employees838
CountryUS
IPO Date2010-10-15

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Phathom Pharmaceuticals, Inc. (PHAT)
  • ARS Pharmaceuticals, Inc. (SPRY)
  • Inhibrx Biosciences, Inc. (INBX)
  • Novavax, Inc. (NVAX)
  • Sana Biotechnology, Inc. (SANA)
  • Pacira BioSciences, Inc. (PCRX)
  • Erasca, Inc. (ERAS)
  • NovaBridge Biosciences (NBP)
IOVA earnings history · IOVA institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.